p53 α-helix mimetics antagonize p53/MDM2 interaction and activate p53

Molecular Cancer Therapeutics

Volumn 4, Issue 6, 2005, Pages 1019-1025

  Chen, Lihong ^a   Yin, Hang ^b   Farooqi, Bilal ^a   Sebti, Said ^a   Hamilton, Andrew D ^b   Chen, Jiandong ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN MDM2; PROTEIN P53; TERPHENYL DERIVATIVE;

ALPHA HELIX; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; BIOMIMETIC MATERIALS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SEQUENCE ALIGNMENT; STRUCTURE-ACTIVITY RELATIONSHIP; TERPHENYL COMPOUNDS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 21344461945     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-04-0342     Document Type: Article

References (25)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
2. Zhang Y, Xiong Y. Control of p53 Ubiquitination and nuclear export by MDM2 and ARF. Cell Growth Differ 2001;12:175-86.
3. Meek DW. p53 Induction: phosphorylation sites cooperate in regulating. Cancer Biol Ther 2003;1:284-6.
4. Prives C, Hall PA. The p53 pathway. J Pathol 1999;187:112-6.
5. 1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 1996;16:2445-52.
6. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998;26:3453-9.
7. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-3.
8. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731-7.
9. Chen L, Agrawal S, Zhou W, Zhang R, Chen J. Synergistic activation of p53 by inhibition of mdm2 expression and DNA damage. Proc Natl Acad Sci U S A 1998;95:195-200.
10. Chen L, Lu W, Agrawal S, Zhou W, Zhang R, Chen J. Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression. Mol Med 1999;5:19-32.
11. Blaydes JP, Gire V, Rowson JM, Wynford-Thomas D. Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2. Oncogene 1997;14:1859-68.
12. Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996;274:948-53.
13. Bottger V, Bottger A, Howard SF, et al. Identification of novel mdm2 binding peptides by phage display. Oncogene 1996;13:2141-7.
14. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303: 844-8.
15. Kutzki O, Park HS, Ernst JT, Orner BP, Yin H, Hamilton AD. Development of a potent Bcl-x(L) antagonist based on α-helix mimicry. J Am Chem Soc 2002;124:11838-9.
16. Orner BP, Ernst JT, Hamilton AD. Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an α-helix. J Am Chem Soc 2001;123:5382-3.
17. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993;13:4107-14.
18. Garcia-Cao I, Garcia-Cao M, Martin-Caballero J, et al. "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J 2003;21:6225-35.
19. Freedman DA, Epstein CB, Roth JC, Levine AJ. A genetic approach to mapping the p53 binding site in the MDM2 protein. Mol Med 1997;3: 248-59.
20. 2 arrest after DNA damage. Science 1998; 282: 1497-501.
21. Landers JE, Haines DS, Strauss JF, George DL. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 1994;9:2745-50.
22. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997;91:325-34.
23. Ljungman M, Zhang F, Chen F, Rainbow AJ, McKay BC. Inhibition of RNA polymerase II as a trigger for the p53 response. Oncogene 1999; 18:583-92.
24. Lu W, Chen L, Peng Y, Chen J. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 2001;20:3206-16.
25. Yin H, Lee GI, Park HS, et al. Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. Angew Chem Int Ed Engl 2005 Apr 29;44(18):2704-7.